We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rapid Benzodiazepine Detoxification Using Flumazenil - 1

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000246
First Posted: September 21, 1999
Last Update Posted: September 8, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yale University
  Purpose
The purpose of this study is to verify the hypothesis that the benzodiazepine antagonist, flumazenil, will reduce acute benzodiazepine withdrawal.

Condition Intervention Phase
Substance-Related Disorders Drug: Flumazenil Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Rapid Benzodiazepine Detoxification Using Flumazenil

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Benzodiazepine withdrawal severity

Enrollment: 10
Study Start Date: January 1993
Study Completion Date: December 1994
Primary Completion Date: December 1994 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000246


Locations
United States, Connecticut
Yale University, Psychiatry
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Scott Woods, M.D. Yale University
  More Information

Publications:
Woods, et al., Soc Neuroscience Abstracts 21: 2098, 1995.

Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000246     History of Changes
Obsolete Identifiers: NCT00000247
Other Study ID Numbers: NIDA-08265-1
R01DA008265 ( U.S. NIH Grant/Contract )
R01-08265-1
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: September 8, 2016
Last Verified: September 2016

Keywords provided by Yale University:
Substance-Related Disorders

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Flumazenil
Antidotes
Protective Agents
Physiological Effects of Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action